Previous 10 | Next 10 |
home / stock / rlftf / rlftf news
Relief Therapeutics Holding (RLFTF) provides an update on the development of ACER-001, a proprietary powder formulation of sodium phenylbutyrate (NaPB) being developed for the treatment of urea cycle disorders (UCDs).UCDs are a group of rare genetic metabolic disorders which can lead to an ex...
GENEVA, SWITZERLAND / ACCESSWIRE / May 18, 2021 / RELIEF THERAPEUTICS Holding AG (SIX:RLF, OTCQB:RLFTF)(" Relief "), a biopharmaceutical company with its lead compound RLF-100 TM (aviptadil) in advanced clinical development to treat severe COVID-19 patients, today provided an update on the ...
GENEVA, SWITZERLAND / ACCESSWIRE / May 17, 2021 / RELIEF THERAPEUTICS Holding AG (SIX:RLF, OTCQB:RLFTF)(" Relief "), a biopharmaceutical company with its lead compound RLF-100 TM (aviptadil) in advanced clinical development to treat COVID-19-induced lung injury, is pleased to see the recent...
Relief Therapeutics (RLFTF) and privately held Swiss pharmaceutical company, APR Applied Pharma Research ((APR)) have signed a binding term sheet for Relief to acquire all outstanding shares of APR. According to the Term Sheet, the APR shareholders will receive at the closing of a transaction...
Acquisition would further diversify Relief's pipeline with both commercial products and clinical-stage programs GENEVA and BALERNA, SWITZERLAND / ACCESSWIRE / May 4, 2021 / RELIEF THERAPEUTICS Holding AG (SIX:RLF, OTCQB:RLFTF)(" Relief "), a biopharmaceutical company with its lead compo...
Relief Therapeutics (RLFTF) and AdVita Lifescience announce that the first patient is expected to be enrolled next week in a Phase 2 trial evaluating the inhaled formulation of RLF-100 for the prevention of COVID-19-related acute respiratory distress syndrome ((ARDS)). The trial is expected t...
GENEVA, SWITZERLAND / ACCESSWIRE / April 19, 2021 / RELIEF THERAPEUTICS Holding AG (SIX:RLF)(OTCQB:RLFTF) (" Relief " or the " Company "), commented today on certain statements made by NeuroRx, Inc., its collaboration partner for the development of RLF-100 TM (aviptadil) pursuant to that ce...
Relief Therapeutics Holding AG (RLFTF): FY Net loss of CHF7.8M (2019: CHF7.5M).EBITDA loss of CHF20.3M (2019: loss of CHF0.9M).Cash of CHF43.1MRelief expects to make continued progress with its development programs and in advancing its business in the months ahead.Pipeline update: RLF-10...
GENEVA, SWITZERLAND / ACCESSWIRE / April 15, 2021 / RELIEF THERAPEUTICS Holding AG (SIX:RLF)(OTCQB:RLFTF) (" Relief " or the " Company "), a biopharmaceutical company with its lead compound RLF-100 TM (aviptadil) in advanced clinical development to treat COVID-19 induced lung injury, today ...
GENEVA, SWITZERLAND / ACCESSWIRE / April 7, 2021 / RELIEF THERAPEUTICS Holding AG (SIX:RLF)(OTCQB:RLFTF) (" Relief " or the " Company "), a biopharmaceutical company with its lead compound RLF-100 TM (aviptadil) in advanced clinical development to treat COVID-19 induced respiratory disorder...
News, Short Squeeze, Breakout and More Instantly...
Mondobiotech Holding AG Basel Company Name:
RLFTF Stock Symbol:
OTCMKTS Market:
Mondobiotech Holding AG Basel Website:
GENEVA, SWITZERLAND / ACCESSWIRE / June 27, 2024 / RELIEF THERAPEUTICS Holding SA (SIX: RLF )(OTCQB: RLFTF )(OTCQB: RLFTY ) (Relief Therapeutics, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, ann...
GENEVA, SWITZARLAND / ACCESSWIRE / May 30, 2024 / RELIEF THERAPEUTICS Holding SA (SIX: RLF )(OTCQB: RLFTF )(OTCQB: RLFTY ) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select rare diseases, today announced the Annual General Mee...
GENEVA, SWITZERLAND / ACCESSWIRE / May 8, 2024 / RELIEF THERAPEUTICS Holding SA (SIX: RLF )(OTCQB: RLFTF )(OTCQB: RLFTY ) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select rare diseases, today announced the formation of its ne...